Issue replacement policy: address changes to the ASPET office. May be obtained, if available, from ASPET at the single copy price. Send Change of address: 47-45; email: dc.elicensing@organge.fr.

—Claims for nondelivery of issues must be made within six (6) months of issue mail date. Missing Issues (domestic and foreign)—ASPET will not honor refunds or replacement requests made outside of the claim time period. Up to two (2) issues will be replaced free of charge per subscription year.

Reprints in large quantities for commercial or academic use may be purchased from ASPET. For information and prices, call 301-634-7063.

Copyright information: Drug Metabolism and Disposition is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. For permission to photocopy or use material electronically from Drug Metabolism and Disposition, see www.copyright.com or contact the Copyright Clearance Center (CCC), Inc., 222 Rosewood Dr., Danvers, MA 01923; telephone: 978-750-8400. Photocopying of articles beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law is allowed, provided that the $20.00-per-copy fee is paid through the CCC. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying. Reproduction of any portion of an article for subsequent republication requires permission of ASPET. Write to the ASPET office at the above address. Requests should include a statement of intended use as well as explicit specifications of the materials to be reproduced.

Disclaimer: The statements and opinions contained in the articles of Drug Metabolism and Disposition are solely those of the individual authors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in any article or advertisement.

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics. All rights reserved. Printed in the U.S.A.
SHORT COMMUNICATIONS


A Novel Bioactivation Pathway for 2-[2-(2,6-Dichlorophenyl)aminophenyl]ethanoic Acid (Diclofenac) Initiated by Cytochrome P450-Mediated Oxidative Decarboxylation. Mark P. Grillo, Ji Ma, Yohannes Teffera, and Daniel J. Waldon ................. 1740

ARTICLES

Species Differences in UDP-Glucuronosyltransferase Activities in Mice and Rats. Hirotada Shiratani, Miki Katoh, Miki Nakajima, and Tsuyoshi Yokoi . . . . . . . . . . . . . 1745

Metabolism, Distribution, and Excretion of a Next Generation Selective Estrogen Receptor Modulator, Lasofoxifene, in Rats and Monkeys. Chandra Prakash, Kim A. Johnson, Clinton M. Schroeder, and Michael J. Potchoiba . . . . . . . . . . . . . . . . 1753

Covalent Binding and Tissue Distribution/Retention Assessment of Drugs Associated with Idiosyncratic Drug Toxicity. Hideo Takakusa, Hiroshi Masumoto, Hideo Yukinaga, Chie Makino, Shintaro Nakayama, Osamu Okazaki, and Kenichi Sudo . . . . . . . . . . . . . . 1770

The Dihydroorotase Inhibitor 5-Aminoorotic Acid Inhibits the Metabolism in the Rat of the Cardio-protective Drug Dexrazoxane and Its One-Ring Open Metabolites. Patricia E. Schroeder, Daywin Patel, and Brian B. Hasinoff . . . . . . . . . . . . . . 1780

Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+/Taurocholate- Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients. Kenya Nakai, Hiromesa Tanaka, Kazuhiro Hanada, Hiroyasu Ogata, Fumitaka Suzuki, Hiro-mitsu Kumada, Atsuko Miyajima, Seiichi Ishida, Momoko Sunouchi, Wataru Habano, Yuichiro Kamikawa, Keiichi Kubota, Junji Kita, Shogo Ozawa, and Yasuo Ohno .......... 1786

Metabolism and Transport of the Citrus Flavonoid Hesperetin in Caco-2 Cell Monolayers. Walter Brand, Petronella A. I. van der Wel, Maarit J. Rein, Denis Barron, Gary Williamson, Peter J. van Bladeren, and Ivonne M. C. M. Rietjens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1794

Cytochrome P450 2C11 5’-Flanking Region and Promoter Mediate in Vivo Suppression by 3-Methylcholanthrene. Rana M. Sawaya and David S. Riddick .................. 1803

Binding of Pimecrolimus and Tacrolimus to Skin and Plasma Proteins: Implications for Systemic Exposure after Topical Application. H. Markus Weiss, Marcel Fresneau, Thomas Moenius, Anton Stuets, and Andreas Billich . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1812

Down-Regulation of the Carcinogen-Metabolizing Enzyme Cytochrome P450 1a1 by Vanadium. Anwar Anwar-Mohamed and Ayman O. S. El-Kadi ................. 1819

Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics. Lifei Wang, Lisa J. Christopher, Donghua Cui, Wenyeng Li, Ramaswamy Iyer, W. Griffith Humphreys, and Donglu Zhang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1828

Continued on next page
Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds. Cuiping Chen, Jeffery L. Stock, Xingrong Liu, Jilin Shi, Jeffrey W. Van Deusen, Debra A. DiMattia, Robert G. Dullea, and Sonia M. de Morais .................................................. 1840

Pharmacokinetics and Brain Penetration of Casopitant, a Potent and Selective Neurokinin-1 Receptor Antagonist, in the Ferret. Elisabeth Minthorn, Thomas Mencken, Andrew G. King, Art Shu, David Rominger, Richard R. Gontarek, Chao Han, Ramesh Bambal, and Charles B. Davis .................................. 1846

Biodistribution of Radiolabeled Ethanol in Rodents. Andrew N. Gifford, Mel Pilar Espaillat, and S. John Gatley ............................................................................. 1853


Metabolism Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic Acid Hydroxyamide (CP-544439), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans. Deepak Dalvie, Theresa Cosker, Tracey Boyden, Sue Zhou, Clinton Schroeder, and Michael J. Potchoiba ............................................................. 1869

Inherent Sexually Dimorphic Expression of Hepatic CYP2C12 Correlated with Repressed Activation of Growth Hormone-Regulated Signal Transduction in Male Rats. Chellappagounder Thangavel and Bernard H. Shapiro .................................................................................. 1884

Identification of Enzymes Involved in the Metabolism of 17α-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth. Shringi Sharma, Junhui Ou, Stephen Strom, Don Mattison, Steve Caritis, and Raman Venkataramanan .................................................................................. 1896

Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes. Masashi Mise, Takanori Hashizume, and Setsuko Komuro .................................................. 1903

The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity. Sarah J. Schriever, Zhiming Wen, Manoli Vourvahis, Philip C. Smith, Michael W. Fried, Angela D. M. Kashuba, and Roy L. Hawke .......................................................... 1909

Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis. Shuso Takeda, Koichiro Misawa, Ikuo Yamamoto, and Kazuhiro Watanabe .......................................................... 1917


Novel Binding Mode of the Acidic CYP2D6 Substrates PACTimide and Its Metabolite R-125528. Masakatsu Kotsuma, Hiroyuki Hanzawa, Yoriko Iwata, Kenji Takahashi, and Taro Tokui ............................................. 1938

Effect of Endotoxin on the Expression of Placental Drug Transporters and Glyburide Disposition in Pregnant Rats. Vanja Petrovic, Jing-Hung Wang, and Micheline Piquette-Miller ..................................................... 1944


Prominent Expression of Xenobiotic Efflux Transporters in Mouse Extraembryonic Fetal Membranes Compared with Placenta. Lauren M. Aleksunes, Yue Cui, and Curtis D. Klaassen ............................................. 1960

ACCELERATED COMMUNICATION


ERRATUM

Correction to “A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro”. .................................................. 1975

SUPPLEMENTAL MATERIAL

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Immunohistochemical detection of Bcrp in placentas of 24-h saline-treated (A–C) and endotoxin-treated (0.5 mg/kg) (D–F) rats. See article by Petrovic et al. on page 1944 of this issue.
Advertise in the publications of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Receive a FREE posting on the ASPET website for 8 weeks with a paid line ad in ASPET's member magazine Molecular Interventions (MI).

- MI is read by over 4,400 members
- Line ads, web postings, and email ads available
- Line ads only $12 per line in MI
- Online postings up within a couple days
- Email ads only $250 per issue

CONTACT FASEB AdNet at 301-634-7156 or email adnet@faseb.org for an ad estimate.
View ASPET rate card and full media kit at www.faseb.org/adnet.

Need to promote open positions, fellowship opportunities, programs, or conferences in pharmacology?

A free service providing email-based alerts for ASPET’s journals!

Customize alerts to meet your needs:

- Announcements
- Future Tables of Contents
- Fast Forward (publish-ahead-of-print) articles
- Table of Contents
- CiteTrack Alerts including:
  - Citation Alerts
  - Keyword & Author Alerts

Create your alerts at:

JPET.aspetjournals.org/subscriptions
PHARMREV.aspetjournals.org/subscriptions
MOLPHARM.aspetjournals.org/subscriptions
DMD.aspetjournals.org/subscriptions
MOLINTERV.aspetjournals.org/subscriptions
Optimizing the Use and Interpretation of In Vitro ADME Studies

SAN FRANCISCO, USA - The Fairmont - 5th November 08

Confirmed Speakers include:

Leslie Z. Benet - Professor of Biopharmaceutical Sciences UCSF, San Francisco, CA, USA “In vitro results and BDDCS in predicting transporter effects on drug absorption, disposition and DDIs of NMEs”

Volker Fischer - Senior Director DMPK and Bioanalysis, Abbott, IL, USA “PBPK vs Allometry: Case examples for predicting human PK during compound selection and early development”

Andrew Parkinson - Founder & CEO XenoTech, Lenexa, KS, USA “Induction of drug-metabolizing enzymes: In vitro studies, IVIVE and the emerging role of xenosensors in endobiotic homeostasis”

Carl C. Peck - Adjunct Professor, UCSF, San Francisco “Learning, confirming, or refuting drug-drug interactions: opportunities in Phase II and III studies.”

Ravi Rahavendran - Associate Director, Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global R&D. La Jolla, CA, USA “Simcyp as a risk prediction and assessment tool in drug discovery and development – selected case examples”

Malcolm Rowland - Professor Emeritus, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK “Predicting human pharmacokinetics: How are we doing?”

Magang Shou - Director of Pharmacokinetics and Drug Metabolism, Amgen Inc. Thousand Oaks, CA, USA “Kinetic approaches and correlation analyses for prediction of clinical drug interactions from in vitro CYP3A4 induction data”

Donald Stanski - MD, Global Head Modelling and Simulation, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA “Creating an integrated modelling and simulation department: lessons learned”

Geoff Tucker - Professor, Academic Unit of Clinical Pharmacology, University of Sheffield, UK “All models are wrong - but some are useful”

John A. Wagner - MD, PhD Executive Director, Clinical Pharmacology, Merck Research Laboratories, Acting Scientific Discipline Integrator, Merck SIMS Rahway, NJ, USA “Strategically Integrated Modelling and Simulation (SIMS) in early and late drug development”

Diane Wang - Director, Clinical Pharmacology, Oncology, Pfizer Global R&D. La Jolla, CA, USA “Application of modelling and simulation in pre-clinical and clinical drug development - case examples”

Walter Wolotsz - Chairman & CEO, Simulations Plus, Inc., CA, USA “Overcoming skepticism in widespread use of M&S in drug discovery and development - 11 years of experience in Simulation Plus”

SHEFFIELD, UK - Mercure St Paul’s Hotel - September 2008

9th Annual Consortium meeting & IVIVE workshops

SAN FRANCISCO, USA - The Fairmont Hotel - November 2008

West Coast USA - IVIVE workshops & Associated seminar

WASHINGTON, USA - The Marriott Hotel - April 2009

East Coast USA - IVIVE workshops & associated seminar

LEIDEN, NETHERLANDS - Holiday Inn - May 2009

European IVIVE workshops & associated seminar

SHEFFIELD, UK - September 2009

10th Annual Consortium meeting & IVIVE workshops

LA JOLLA, USA - The Marriott Hotel - November 2009

West Coast USA - IVIVE workshops & associated seminar

The two-day workshops will take place prior to and after each of the seminars / meetings, led by Professor Amin Rostami of the University of Sheffield

These workshops cover aspects of in vitro – in vivo extrapolation (IVIVE) in the prediction of absorption, distribution, clearance and drug-drug interactions.

The courses are designed to give a general background to PBPK and IVIVE involving prediction of concentration-time profiles. All course material is set within a context relevant to drug discovery and development. All courses involve computer-based hands-on problem solving sessions.

Due to the success of the previous workshops in Philadelphia, Basel, Baltimore, Prague and Arosa and the high demand for these interactive workshops, we recommend early booking.